A New York (NY) judge struck down most of the state’s cannabis regulations last week before scaling back on their decision.
Cannabis leaf and gavel. Image Credit: © Victor Moussa - stock.adobe.com
Last week, an Albany County Supreme Court judge ruling appeared to suggest that they were going to be striking down all New York (NY) cannabis regulations. The recent ruling was in regard to a lawsuit filed by Leafly, a cannabis website. According to AP News (1), Leafly “challenged the state’s rules barring marijuana dispensaries from advertising on third-party platforms.”
The judge’s decision suggested that it was going to be striking down almost all of New York’s cannabis regulations involving adult-use (2). NY State Supreme Court Justice Kevin Bryant amended their recent ruling the following day (1-3). Reuters mentioned that the judge had “criticized” the Office of Cannabis Management, as well as the New York Cannabis Control Board’s reaction to Leafly. “Here, there is no indication that any evidence was actually placed before the administrative agency,” Justice Bryant wrote (2). “It is not counsel's role to develop and outline a rational argument in favor of the regulations after the fact.”
In the amended ruling, Justice Bryant mentioned that only a few regulations specifically regarding the handling of advertising and third-party marketing restrictions (2). By the time the amended ruling was made public, news agencies and others had been reporting the Big Apple State’s cannabis regulations being entirely struck down (1). Unhappy with the misinterpreted ruling, State Senator Jeremy Cooney, who is a part of the state’s Senate cannabis subcommittee, released a statement (1): “State Supreme Court decision was another setback in a series of blows New York’s adult-use cannabis market has faced since legalization, three years ago”. Senator Cooney added that, “While some changes to marketing regulations are needed, the decision by the Court to throw out all agency regulations will ultimately slow progress at a time when we need to more aggressively combat illicit shops to grow a stronger, more-equitable legal market.” With the amended ruling clarifying that the entire cannabis regulations for the state weren’t voided, the Office of Cannabis Management has commented that they are “reviewing the corrected decision” (1).
Recreational cannabis was first legalized in New York State in 2021 (4). The process has been very slow. This has been seen in a lack of regulatory enforcement, additional legal challenges, a lagging licensing process, and an abundance of illegal establishments (1).
Aside from the growing frustrations of New York’s slow cannabis program rollout, Leafly released a statement highlighting their support for the state’s cannabis industry (1): “It’s impossible to overstate the importance of providing consumers with choices, and educational information when making purchasing decisions.” The cannabis website added how, “It is critically important that licensed-retailers have equal access to important advertising and marketing tools to help them succeed in a competitive landscape.”
References
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.